Home LiteratureArticle Details
PMID: 13069650 Published · ppublish English Journal Article

The experimental production of combination forms of virus. II. A study of serial passage in the allantoic sac of agents that combine the antigens of two distinct influenza A strains.

The Journal of experimental medicine ·Vol. 98 ·No. 1 ·1953-07-00 ·Pages 53-70

HIRST GK, GOTLIEB T

Abstract

Double infection of the allantoic sac with Melbourne and WSN viruses induced the formation of a combination virus, which had some of the antigenic properties of both parents and which maintained itself through serial passage in the chorioallantoic sac. In the course of prolonged passage in the egg, three varieties of combination virus were found. The first (X(1)) occurred in ten passages and was characterized as follows: X(1) was produced in and could be successfully passed from those chick embryos that had received very large inocula of virus. The X(1) hemagglutinin was efficiently inhibited by both M and W antisera. Each passage fluid, containing X(1) as the predominant strain, also contained large amounts of the parent forms M and W. It is very likely that X(1) reverted to parent types of virus at a high rate. The second variety (X(2)) arose from the passage series of X(1) and was carried for approximately 20 passages without definite alteration in its character. It differed from X(1) in that it had the ability to appear as the predominant form occasionally in embryos that had received a limiting infective dilution of virus. Because of this, it seems probable that X(2) reverted to parent types at a slower rate than X(1). Like X(1), this virus was never obtained in pure form and suspensions in which it predominated contained large amounts of M and W, especially the former. Good evidence was obtained that X(2) reverted to M and W virus while multiplying in the chorioallantoic sac. X(3) was derived from passage of X(2) virus after 32 transfers and can be characterized in several ways: (a) X(3) yielded the only X(3) fluids on passage in eggs. This was in striking contrast to X(2) which could not be passed without giving rise to some fluids in which M and W predominated, (b) The X(3) hemagglutinin was weakly inhibited by all but the highest concentrations of M serum, but was strongly inhibited by W serum. X(2) was readily inhibited by relatively small amounts of both sera. (c) X(3) virus, after several passages at limiting dilutions, was neutralized to a highly significant degree by specific M and W sera. This is not necessarily an essential difference from the behavior of X(2) since technical difficulties (large amounts of M and W in X(2) fluids) may have prevented the demonstration of equally striking double neutralization of this virus, (d) After five limiting dilution passages, the X(3) virus retained the characteristics listed under (a) to (c). It is felt that the foregoing facts justify the conclusion that X(3) is a stable virus which combines some of the specific antigens of two parent types.

Keywords
INFLUENZA VIRUSES
MeSH Terms
Animals Antigens Chick Embryo Humans Immune Sera Influenza, Human Orthomyxoviridae Serial Passage
Chemicals
Antigens Immune Sera
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
HIRST G K
GOTLIEB T
References (1)
1 references, click to expand
  1. The experimental production of combination forms of virus. I. Occurrence of combination forms after simultaneous inoculation of the allantoic sac with two distinct strains of influenza virus.
    J Exp Med. 1953 Jul;98(1):41-52 PMID: 13069649
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1953-07-00
Pages
53-70
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2136272
Subset
OM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]